Leerink Partners analyst David Risinger has reiterated their bullish stance on PCVX stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
David Risinger has given his Buy rating due to a combination of factors related to Vaxcyte’s developmental progress and future potential. The company is making significant strides with its VAX-31 program, as evidenced by the advancement of its Phase 2 Infant study to stage 2. This progression followed a positive assessment of safety and tolerability from stage 1, and the study’s continuation aims to further evaluate these metrics along with immunogenicity in infants.
In addition to the promising progress of VAX-31, Vaxcyte has several upcoming catalysts that could drive further value. The management plans to release Phase 2 Infant topline results for VAX-24 by the end of the first quarter of 2025, with additional data expected later in the year. Moreover, the initiation of a Phase 3 pivotal study for VAX-31 in adults is anticipated in mid-2025, with key data disclosures to follow in 2026. These developments, along with the potential progression of the Group A Strep vaccine candidate, underscore Vaxcyte’s strong pipeline and growth prospects, justifying the Buy rating.
Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and AbbVie. According to TipRanks, Risinger has an average return of 12.8% and a 58.86% success rate on recommended stocks.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $157.00 price target.